The use of electromagnetic fields for healing has been known from time immemorial. Even many centuries ago, magnets were used for regenerating purposes. It is only in the past 50 years that specific use of electromagnetic fields that are of help in tissue regeneration or degeneration have been clearly defined. A lot of research had gone into the use of electromagnetic fields but different applications were not specific enough to cause the desired changes. In the last few decades, there has been a lot of research to establish a scientific basis for the use of electromagnetic device in the treatment of various illnesses.
In Yuri Gagarin’s historic flight to space, he returned in near critical condition after only one hour and forty-eight minutes in space. Clearly, there was some vital element missing in space that we receive on earth. Yuri had plenty of food, water and oxygen and since the flight was less than 2 hours, he only needed oxygen. The critical missing element appeared to be the earth’s magnetic field. Since that first flight, pulsed magnetic devices have been used in every space suit and space station. Further studies have been done on earth (zero field studies) with both laboratory animals and human subjects. In a matter of hours without exposure to healthy PEMF’s, cell metabolism begins to break down causing bone loss, muscle weakness, depressed metabolism, disorientation and depression.
It is known that electromagnetic fields of certain frequency ranges and intensities are indigenous to living tissues and it has been found that inciting the inherent resonance by exogenous treatment using electromagnetic fields, electric fields and magnetic fields can induce cellular regeneration and degeneration processes.
While doing research work on the Magnetic Resonance Imaging (MRI) alterations in cell behavior by radio frequencies and magnetic fields at the Indian Airforce (IAF), Dr Vasishta invented Sequentially Programmed Magnetic Field (SPMF) Therapy. Dr Vasishta’s extensive work over the last 15 years has led to fine-tuning magnetic field strength and frequency to accurately target specific tissue and cell types based on proton density.
SPMF is a comprehensive system for inducing cellular regeneration and/or degeneration processes and methods of treatment based on such processes through generating and applying a sequentially programmed magnetic field (SPMF) therapy to the area to be treated.
Osteoarthritis (OA) is caused by progressive degeneration of articular cartilage. As such, the articular cartilage has very limited regenerative capacity. Exposure to SPMF therapy sensitizes and re-creates the missing physiological piezoelectric stimulus necessary for cartilage regeneration. A study to demonstrate the efficacy of SPMF therapy on 195 patients (390 knees) with clinically and radiologically confirmed Osteoarthritis of the knee was conducted by Wg Cdr (Dr) VG Vasishta (Retd) and published in the Scientific Medicine Journal in 2009. The results showed an increase in cartilage thickness measured using MRI at 3 months follow-up compared to pre-treatment values.
Developing an effective treatment for Cancer continues to be the prime focuses of Medical Research, and, in recent years, several treatment modalities have emerged. Although some of these have shown promise in the treatment of cancer in early stages, their application in the terminal stages of the disease is very limited owing to serious adverse events associated with cancer therapy. Wg Cdr (Dr) VG Vasishta conducted a study consisting of 123 patients, suffering from various terminal stages organ cancers. All the patients had completed standard modalities of treatment such as chemotherapy, radiotherapy and surgery, were on palliative care, and had come voluntarily for the treatment. The patients were exposed to SPMF Therapy daily for 1 hour, for 28 consecutive days and were assessed using the Karnofsky Performance scale scores before and after exposure. The patients consistently showed significant improvement in KPS score after exposure to SPMF therapy. The patients also got considerable pain relief after the therapy. Evidently, these findings can initiate a new strategy for terminal palliative care of cancer using SPMF therapy.
The incidence of primary brain tumors in India is estimated to be around 2.4% in spite of the under-reporting and lack of a completely functional cancer registry. Gliomas account for about 60% of all brain tumor cases and 7.89% from amongst them are Glioblastoma Multiforme (GBM). Complete surgical resection with radiotherapy, with or without adjuvant chemotherapy is presently the standard treatment for GBM. Despite the usage of novel drugs and combination therapies, the low survival rates emphasize the need for a novel therapy that can fulfill an unmet clinical need. There has not been till date a single case of a cure for GBM and it is directly related to the diffuse nature of invasion of the cells into the brain parenchyma and their resistances to both natural apoptosis and treatment modalities like chemotherapy and radiotherapy. Wg Cdr (Dr) VG Vasishta (Retd) at SBF Healthcare and Research center, Bangalore, conducted this study. A total of 20 patients with confirmed recurrent cases of GBM, subsequent to surgery and radiotherapy, were recruited for the study. All of them were evaluated for their pre-treatment Karnofsky Performance Scale (KPS) scores to be compared with the post treatment quality of life assessment. Survival analysis was conducted on the patient cohort from the time of conclusion of SPMF therapy. Results showed, SPMF therapy offers a new ray of hope to those who suffer from recurrent GBM in a clinical stage where all other modalities of therapies are deficient to either treat the condition or improve the quality of life.
SBF Healthcare and Research Center is actively doing clinical projects under various aspects of malignant brain tumour patients, Osteoarthritis and Diabetes Mellitus. In future SPMF therapy will benefit many diseases or conditions like neuro degeneration conditions such as the age-related progressive loss of nerve cells, Alzheimer's, Parkinson's, ALS, and Huntington's disease, retinal degeneration, and other damage to sensory systems (e.g., visual, auditory, somatosensory). SPMF therapy holds potential to treat stroke, head and spinal trauma, epilepsy, in drug and alcohol abuse. SPMF therapy may also offer relief in infectious diseases, in exposure to industrial and environmental toxicants, and, perhaps, in mental disorders and chronic pain.
Following are some of the publications in peer-reviewed journals.